Incretin-based drugs and renoprotection-is hyperfiltration key?
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Lennart
L
Tonneijck
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Mark M
MM
Smits
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Daniël H
DH
van Raalte
Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, The Netherlands.
Marcel H A
MH
Muskiet
D000818:Animals; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D054873:Dipeptidyl-Peptidase IV Inhibitors / Q000627:therapeutic use*; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism*; D006801:Humans; D054795:Incretins / Q000378:metabolism* / Q000627:therapeutic use*; D018027:Receptors, Glucagon / Q000819:agonists*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D054795:Incretins; D018027:Receptors, Glucagon; D052216:Glucagon-Like Peptide 1